Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

Objectives To assess 52-week safety and efficacy of bimekizumab in patients with active psoriatic arthritis (PsA) and prior inadequate response/intolerance to tumour necrosis factor inhibitors.Methods Patients completing the 16-week phase III double-blind, placebo-controlled BE COMPLETE (NCT03896581...

詳細記述

書誌詳細

主要な著者:	Robert Landewé, Joseph F Merola, Laure Gossec, Frank Behrens, Ana-Maria Orbai, Philip J Mease, Iain B McInnes, Yoshiya Tanaka, Dafna D Gladman, Laura C Coates, Alice B Gottlieb, Vishvesh Shende, Jason Coarse, Christopher T Ritchlin, Richard B Warren, Akihiko Asahina, Barbara Ink, Rajan Bajracharya
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMJ Publishing Group 2026-04-01
シリーズ:	RMD Open
オンライン･アクセス:	https://rmdopen.bmj.com/content/20/1/e043855.full
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!